Joe Walsh, at 79, is undergoing a groundbreaking treatment for Alzheimer's at Brigham and Women's Hospital. This involves an experimental nasal spray containing a monoclonal antibody intended to reduce brain inflammation, a notable deterioration factor in Alzheimer's progression. Walsh is the first Alzheimer’s patient to receive this treatment, which may also have future applications for other diseases. While initial tests show a reduction in inflammation, the impact on cognition remains uncertain. Dr. Howard Weiner, involved in the treatment's development, highlights its uniqueness in tackling inflammation compared to existing therapies that address toxic protein buildup.
The nasal spray contains an experimental monoclonal antibody meant to reduce the Alzheimer's-related inflammation in Walsh's brain, marking a novel approach to treatment.
Dr. Howard Weiner expresses optimism about the experimental treatment, noting its potential to address inflammation, a critical aspect of Alzheimer's disease progression.
Collection
[
|
...
]